Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest Pharma-VC Experiment: Arteaus Gets $18M For Migraine Drug Licensed From Lilly

This article was originally published in The Pink Sheet Daily

Executive Summary

Atlas Venture and OrbiMed Advisors have launched a virtual company to support development of a single asset, which Lilly can buy back after a Phase II trial.

You may also be interested in...



Lilly’s Venture Strategy Matures As PoC Data Catalysts Approach

As part of a new R&D investment approach, Eli Lilly has partnered with TVM Capital and HealthCare Ventures, which have raised $250 million and funded the start of eight single-molecule companies. Corporate Business Development VP Darren Carroll discussed how the company’s venture initiative has evolved during Elsevier’s Pharmaceutical Strategic Alliance conference Sept. 25.

With Partner Lilly, TVM Capital Gets A Canadian Makeover

One of two venture firms signed up to run an Eli Lilly “mirror portfolio” of single-asset companies, venerable TVM Capital has made significant changes to get its new model off the ground.

Financings Of The Fortnight: Life Science Venture Funding Not Necessarily On The Decline

Plus news on recent financings by Foundation Medicine, Ultragenyx, Labrys Biologics, Solstice Biologics and Sarepta Therapeutics.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel